Last reviewed · How we verify

Actrapid® (Insulin) — Competitive Intelligence Brief

Actrapid® (Insulin) (Actrapid® (Insulin)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin (short-acting/rapid-acting). Area: Diabetes.

phase 3 Insulin (short-acting/rapid-acting) Insulin receptor (IR) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Actrapid® (Insulin) (Actrapid® (Insulin)) — SepNet - Critical Care Trials Group. Actrapid is a rapid-acting human insulin that binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Actrapid® (Insulin) TARGET Actrapid® (Insulin) SepNet - Critical Care Trials Group phase 3 Insulin (short-acting/rapid-acting) Insulin receptor (IR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin (short-acting/rapid-acting) class)

  1. SepNet - Critical Care Trials Group · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Actrapid® (Insulin) — Competitive Intelligence Brief. https://druglandscape.com/ci/actrapid-insulin. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: